These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 15654898

  • 1. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.
    Moayeri H, Oloomi Z.
    Arch Iran Med; 2006 Oct; 9(4):329-34. PubMed ID: 17061604
    [Abstract] [Full Text] [Related]

  • 3. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Oct; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 4. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
    Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ.
    N Engl J Med; 1990 Sep 13; 323(11):713-9. PubMed ID: 2388669
    [Abstract] [Full Text] [Related]

  • 5. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L, Gurrado R, Zecchino C, Manolo F, De Sanctis V, Cisternino M, Caruso-Nicoletti M, Galati M.
    J Pediatr Endocrinol Metab; 1998 Sep 13; 11 Suppl 3():845-9. PubMed ID: 10091155
    [Abstract] [Full Text] [Related]

  • 6. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct 13; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 7. Growth and puberty in thalassemia major.
    Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De Simone M, Arcuri VM, Anastasi S.
    J Pediatr Endocrinol Metab; 2003 Mar 13; 16 Suppl 2():259-66. PubMed ID: 12729401
    [Abstract] [Full Text] [Related]

  • 8. [Growth and endocrine function in major thalassemia].
    Pérignon F, Brauner R, Souberbielle JC, de Montalembert M, Girot R.
    Arch Fr Pediatr; 1993 Oct 13; 50(8):657-63. PubMed ID: 8002739
    [Abstract] [Full Text] [Related]

  • 9. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT.
    Ann Hematol; 2012 Jul 13; 91(7):1107-14. PubMed ID: 22281991
    [Abstract] [Full Text] [Related]

  • 10. Thyroid function in thalassaemia major.
    Senanayake MP, Suraweera SA, Hubert HD.
    Ceylon Med J; 1999 Dec 13; 44(4):166-8. PubMed ID: 10895267
    [Abstract] [Full Text] [Related]

  • 11. Short stature and body proportion in thalassaemia.
    Caruso-Nicoletti M, De Sanctis V, Capra M, Cardinale G, Cuccia L, Di Gregorio F, Filosa A, Galati MC, Lauriola A, Malizia R, Mangiagli A, Massolo F, Mastrangelo C, Meo A, Messina MF, Ponzi G, Raiola G, Ruggiero L, Tamborino G, Saviano A.
    J Pediatr Endocrinol Metab; 1998 Dec 13; 11 Suppl 3():811-6. PubMed ID: 10091151
    [Abstract] [Full Text] [Related]

  • 12. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Dec 13; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 13. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Dec 13; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

  • 15. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul 21; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 16. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Jul 21; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 17. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Jul 21; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 18. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT, Yassin MA, De Sanctis V.
    Acta Biomed; 2018 Feb 16; 89(2-S):27-32. PubMed ID: 29451226
    [Abstract] [Full Text] [Related]

  • 19. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 20. Low bone mineral density in adolescents with beta-thalassemia.
    Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ.
    Ann N Y Acad Sci; 2005 Aug 15; 1054():462-6. PubMed ID: 16339698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.